Vax2Muc

Next generation vaccines against gastrointestinal mucosal pathogens, using helicobacter pylori as model pathogen.

In recent years, addressing antimicrobial resistance (AMR), a threat that could jeopardise large segments of the global population, has been highlighted as an urgent issue. Unfortunately, the task of developing novel vaccines remains highly challenging, particularly for those tackling bacterial infections affecting specific areas such as the gastrointestinal tract. In this context, the EU-funded Vax2Muc project will concentrate on the development of novel vaccination technologies which overcome local tolerance and induce protective immunity on mucosal surfaces. Helicobacter pylori, a chronic bacterial infection, is used as a model organism to evaluate, optimise and prioritise different vaccination strategies. This infection is known to afflict approximately 50 % of the population and has the potential to progress into gastric cancer. The project’s objectives include the thorough evaluation of vaccine candidates in terms of both immunogenicity and safety.

This is a Horizon Europe Health Cluster Project with a start date of 14th April 2023  and a budget of €8,219,842.

AMBER Researcher & Project Partner: Professor Ed Lavelle, TCD

Project Website: https://www.vax2muc.eu/